Business Wire

25 Years of Trust, Quality, and Health: SFI Health™ celebrates Equazen® milestone, the brand of food supplements developed to support cognitive needs

26.3.2025 08:00:00 CET | Business Wire | Press release

Share

- From a pioneering intuition on the benefits of essential fatty acids for the human brain to becoming a global brand trusted by families and healthcare professionals

SFI Health is proud to celebrate the 25th anniversary of Equazen®, a globally recognized, science-based food supplement designed to nourish, enhance, and support the brain's potential. Since its market debut in 2000, Equazen® has remained committed to innovation and pharma-quality standards, establishing itself as a leading brand in cognitive health supplements.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250326323152/en/

Discover Equazen® comprehensive range: multiple pharmaceutical formats and sizes to support the cognitive health of infants, children and teenagers. For more info visit www.equazen.com

The story of Equazen® began in 1999 in the UK with Prof. Horrobin’s groundbreaking research. Guided by his intuition, he researched certain pediatric cognitive function disorders stemming from a lack of essential fatty acids and their precursors. This insight led to the development of the first Equazen® product, originally known as Eye Q.

The product featured a unique combination of essential fatty acids, setting the foundation for Equazen®’s evolution while aligning with the company’s core philosophy: to harness the power of naturally sourced ingredients and adopt a pharma-quality approach to food supplements.

Since the publication of its first clinical evidence in 2005, Equazen® has been supported by over two decades of clinical trials. As a result, the brand is trusted globally by business partners, families and healthcare professionals to enhance learning capabilities, concentration, and overall cognitive well-being.

At the same time, Equazen® has evolved into multiple pharmaceutical formats and sizes to support the cognitive health of infants, children and teenagers.

One of the latest innovations is Equazen® Jelly, which combines the unique blend of essential fatty acids with a fruity flavor designed to appeal to picky eaters. Additionally, its patent-protected technology ensures the jelly is easy to swallow and promotes better natural absorption.

Matthew Brabazon, GM of SFI Heath EMEA, the regional entity of SFI Health, commented: It’s been an incredible journey watching Equazen® grow over the past 25 years to become a trusted brand globally. Looking ahead, we remain focused on the future and have exciting plans to continue bringing innovation to the market.”

Zbyszek Czop, Managing Director of Qpharma Sp. z o.o., distributor of Equazen® in Poland said: Earning the trust of doctors through the positive results of clinical studies on Equazen® is incredibly gratifying. Healthcare professionals now believe that Equazen® can make a meaningful difference for children, particularly those with behavioral disorders.”

Kirsten Jorsal, Founder of Novasel EU,distributor of Equazen® in Denmark added: Equazen® is a unique fatty acid supplement, distinguished by its balanced blend of polyunsaturated fatty acids, with a notably higher EPA content compared to DHA. Along with its strong clinical documentation, it stands apart from other fish oil supplements. Working with this product for so many years has been both rewarding, and receiving feedback from satisfied families has been truly fulfilling.”

A deep knowledge of consumers’ needs continues to guide the brand and inspires future innovations. The Equazen® range is proudly available in 30 countries across all continents, and the company is dedicated to expanding its reach, ensuring more consumers worldwide can benefit from its offerings.

About SFI Health

SFI Health is a global leader in natural healthcare, specialized in the design, development and commercialization of clinically researched products in the areas of microbiome, cognition and wellbeing.

Guided by the belief in the healing potential of natural products, SFI Health combines a rigorous pharma-based approach with the benefits of naturally sourced solutions.

An extensive network of trusted business partners enables the company, headquartered in Australia, to market its own brands, reaching consumers in over 50 countries. The EMEA SFI Health regional office in Lugano, Switzerland, manages commercial operations across Europe, Middle East and Africa.

SFI Health is committed to fostering confidence in natural healthcare by sharing state-of-the-art research, technical expertise and comprehensive sales & marketing resources with consumers, healthcare professionals and partners worldwide.

For more information go to sfihealth.com or follow us SFI Health on LinkedIn.

About Equazen®

Equazen® is a science-based globally branded food supplement designed and studied to help nourish, enhance, and support the human brain’s potential across all life stages.

Each product of the Equazen® range contains a balanced unique combination of essential fatty acids (Omega 3 and Omega 6), which has been clinically proven for more than 20 years to assist with learning capabilities, concentration and healthy brain development.

Equazen® is available in multiple pharmaceutical formats and sizes to support optimal cognitive functions from infants to teenagers.

Currently marketed in 30 countries globally, Equazen® is widely recommended by healthcare professionals and trusted by families for the last 25 years.

Equazen® aims to advance human health naturally, delivering expertly formulated products that empower individuals to reach their cognitive potential.

For more info visit www.equazen.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20250326323152/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release

Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize

Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release

Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b

LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 07:09:00 CEST | Press release

The deal would be part of a 360° partnership with Randstad involving: Proposed acquisition of USD 500M+ (€469M) business, primarily across Aerospace & Defence, Automotive, Utilities and BFS Five-year IT services partnership to drive AI-enabled transformation for Randstad’s India Global Capability Center Strategic talent MSP to support LTM’s expanding global workforce LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through cen

Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 07:00:00 CEST | Press release

Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well

Global Stars Ahn Hyo-seop and Khalid Release New Cross-Market Single “Something Special” via FANDOM Today22.5.2026 06:00:00 CEST | Press release

Produced by Woo “RAINSTONE” Rhee and Grammy Award-Winning Producer Troy “R8DIO” JohnsonStream the Single HERE For approved imagery, please download HERE Today marks the official release of “Something Special,” the highly anticipated cross-market collaboration from international star Ahn Hyo-seop and multi-platinum recording artist Khalid, available now via FANDOM on all major streaming platforms. Stream the single HERE. Musicow will also release an official music video in June, highlighting the unique chemistry between Ahn Hyo-seop and Khalid while bringing the song’s cross-cultural collaboration to life on screen. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522928365/en/ Ahn Hyo-seop, globally recognized for his breakout role as “Jinu,” the leader of demon boy band Saja Boys in Netflix’s animated phenomenon KPop Demon Hunters, joins forces with Grammy-nominated artist Khalid for a genre-blending release that bridges t

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye